Samer Haidar

713 total citations
27 papers, 541 citations indexed

About

Samer Haidar is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Samer Haidar has authored 27 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Samer Haidar's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and Prostate Cancer Treatment and Research (5 papers). Samer Haidar is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Protein Kinase Regulation and GTPase Signaling (6 papers) and Prostate Cancer Treatment and Research (5 papers). Samer Haidar collaborates with scholars based in Germany, Syria and Spain. Samer Haidar's co-authors include Rolf W. Hartmann, Joachim Jose, Peter B. Ehmer, Christine Batzl‐Hartmann, Marc Le Borgne, David Knoff, Keith L. Ligon, Ahmed Idbaïh, Patrick Y. Wen and Bernhard Wünsch and has published in prestigious journals such as Nature Biotechnology, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Samer Haidar

27 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samer Haidar Germany 12 232 96 93 91 87 27 541
Shu‐Ping Wang China 17 484 2.1× 75 0.8× 75 0.8× 45 0.5× 101 1.2× 36 919
Malkhey Verma India 15 430 1.9× 99 1.0× 40 0.4× 22 0.2× 53 0.6× 43 700
Mariagrazia Distefano Italy 14 374 1.6× 265 2.8× 100 1.1× 97 1.1× 96 1.1× 20 746
Claire E. Knezevic United States 11 207 0.9× 259 2.7× 20 0.2× 68 0.7× 96 1.1× 26 542
Paul Shapiro United States 18 469 2.0× 124 1.3× 24 0.3× 38 0.4× 100 1.1× 31 669
Laura Caboni Ireland 9 289 1.2× 74 0.8× 87 0.9× 51 0.6× 76 0.9× 11 441
Manuela Gridling Austria 13 672 2.9× 269 2.8× 35 0.4× 84 0.9× 126 1.4× 17 1.0k
Raynard L. Bateman United States 12 754 3.3× 116 1.2× 200 2.2× 102 1.1× 42 0.5× 15 1.1k
Mark R. Witmer United States 16 378 1.6× 104 1.1× 23 0.2× 26 0.3× 116 1.3× 29 893
Swati Prasad United States 13 558 2.4× 74 0.8× 94 1.0× 24 0.3× 31 0.4× 16 833

Countries citing papers authored by Samer Haidar

Since Specialization
Citations

This map shows the geographic impact of Samer Haidar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samer Haidar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samer Haidar more than expected).

Fields of papers citing papers by Samer Haidar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samer Haidar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samer Haidar. The network helps show where Samer Haidar may publish in the future.

Co-authorship network of co-authors of Samer Haidar

This figure shows the co-authorship network connecting the top 25 collaborators of Samer Haidar. A scholar is included among the top collaborators of Samer Haidar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samer Haidar. Samer Haidar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haidar, Samer, Ángel Amesty, Claudia Götz, et al.. (2024). 1,2,3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors. Bioorganic & Medicinal Chemistry. 105. 117727–117727. 1 indexed citations
2.
Haidar, Samer, et al.. (2020). Autodisplay of human PIP5K1α lipid kinase on Escherichia coli and inhibitor testing. Enzyme and Microbial Technology. 143. 109717–109717. 5 indexed citations
3.
Haidar, Samer, Christelle Marminon, Waël Zeinyeh, et al.. (2019). QSAR Model of Indeno[1,2-b]indole Derivatives and Identification of N-isopentyl-2-methyl-4,9-dioxo-4,9-Dihydronaphtho[2,3-b]furan-3-carboxamide as a Potent CK2 Inhibitor. Molecules. 25(1). 97–97. 12 indexed citations
4.
Haidar, Samer, Ángel Amesty, Pedro Martín-Acosta, et al.. (2019). Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors. Bioorganic Chemistry. 95. 103520–103520. 13 indexed citations
5.
Haidar, Samer, et al.. (2019). Development of an in vitro screening assay for PIP5K1α lipid kinase and identification of potent inhibitors. FEBS Journal. 287(14). 3042–3064. 7 indexed citations
6.
Haidar, Samer, et al.. (2019). In Vitro and In Silico Evaluation of Bikaverin as a Potent Inhibitor of Human Protein Kinase CK2. Molecules. 24(7). 1380–1380. 19 indexed citations
7.
Vordenbäumen, Stefan, et al.. (2018). Human αS1-casein induces IL-8 secretion by binding to the ecto-domain of the TLR4/MD2 receptor complex. Biochimica et Biophysica Acta (BBA) - General Subjects. 1863(3). 632–643. 11 indexed citations
8.
Haidar, Samer, et al.. (2018). Synthesis and biological evaluation of novel 2 (4`-hydroxynaphthyl) chromen-4-one as a CK2 inhibitor.. PubMed. 73(4). 191–195. 1 indexed citations
9.
Haidar, Samer, Zouhair Bouaziz, Christelle Marminon, et al.. (2017). Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining. Pharmaceuticals. 10(1). 8–8. 29 indexed citations
10.
Haidar, Samer & Rolf W. Hartmann. (2017). Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.. PubMed. 72(9). 529–536. 3 indexed citations
11.
Stevens, Mark M., Cécile L. Maire, Nigel Chou, et al.. (2016). Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nature Biotechnology. 34(11). 1161–1167. 74 indexed citations
12.
Verreault, Maïté, Charlotte Schmitt, Lauriane Goldwirt, et al.. (2015). Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas. Clinical Cancer Research. 22(5). 1185–1196. 81 indexed citations
13.
Borgne, Marc Le, Samer Haidar, Olivier Duval, Bernhard Wünsch, & Joachim Jose. (2015). 1st Joint European Conference on Therapeutic Targets and Medicinal Chemistry (TTMC 2015). Pharmaceuticals. 9(1). 1–1. 36 indexed citations
14.
15.
Haidar, Samer, et al.. (2013). Development and Validation of RP-HPLC Method for Analysis of Four UV Filters in Sunscreen Products. 3 indexed citations
16.
Haidar, Samer, et al.. (2012). DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR DETERMINATION OF CLOPIDOGREL IN TABLETS Research Article. 1 indexed citations
17.
Haidar, Samer, et al.. (2003). Effects of novel 17α-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. The Journal of Steroid Biochemistry and Molecular Biology. 84(5). 555–562. 81 indexed citations
18.
Haidar, Samer & Rolf W. Hartmann. (2002). C16 and C17 Substituted Derivatives of Pregnenolone and Progesterone as Inhibitors of 17α‐Hydroxylase‐C17, 20‐lyase: Synthesis and Biological Evaluation. Archiv der Pharmazie. 335(11-12). 526–534. 13 indexed citations
19.
Hartmann, Rolf W., Peter B. Ehmer, Samer Haidar, et al.. (2002). Inhibition of CYP 17, a New Strategy for the Treatment of Prostate Cancer. Archiv der Pharmazie. 335(4). 119–128. 49 indexed citations
20.
Haidar, Samer, Christian D. Klein, & Rolf W. Hartmann. (2001). Synthesis and Evaluation of Steroidal Hydroxamic Acids as Inhibitors of P450 17 (17α-Hydroxylase/C17-20-Lyase). Archiv der Pharmazie. 334(4). 138–140. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shu‐Ping Wang Breakdown of academic impact, for papers by Malkhey Verma Breakdown of academic impact, for papers by Mariagrazia Distefano Breakdown of academic impact, for papers by Claire E. Knezevic Breakdown of academic impact, for papers by Paul Shapiro Breakdown of academic impact, for papers by Laura Caboni Breakdown of academic impact, for papers by Manuela Gridling Breakdown of academic impact, for papers by Raynard L. Bateman Breakdown of academic impact, for papers by Mark R. Witmer Breakdown of academic impact, for papers by Swati Prasad
Rankless by CCL
2026